US2020232973A1PendingUtilityA1

Pharmaceutical Composition for Cancer Treatment

64
Assignee: SHIONOGI & COPriority: Mar 29, 2017Filed: Jan 2, 2020Published: Jul 23, 2020
Est. expiryMar 29, 2037(~10.7 yrs left)· nominal 20-yr term from priority
Inventors:Tetsuya YoshidaYujiro KidaniMitsunobu MatsumotoTakayuki KanazawaSatomi ShinonomeKanji HojoNaganari OhkuraShimon SakaguchiAtsushi TanakaHisashi WadaAtsunari KawashimaNorio Nonomura
A61K 35/17C07K 2317/76C07K 2317/732C07K 16/2866C07K 16/2827C07K 16/2818A61K 2039/507A61P 35/00A61K 2039/505A61K 9/0019A61K 2039/572A61K 47/60A61K 47/6435A61K 47/6883G01N 33/5011A61K 39/39533
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure provides a method of measuring an efficacy of a drug composition for cancer and a method for treating a cancer by administering to a subject an effective amount of a pharmaceutical composition having a polypeptide that binds to a peptide produced by cDNA of GenBank ACC No. NM_005201.3 or NM_007720.2.

Claims

exact text as granted — not AI-modified
1 . A method of measuring an efficacy of a drug composition for cancer in a subject in need thereof, comprising
 administering the pharmaceutical composition to the subject; and   measuring an ability to stimulate Fc gamma receptors (FcgR) on effector cells in the subject.   
     
     
         2 . The method according to  claim 1 , wherein the method treats cancer in the subject. 
     
     
         3 . The method according to  claim 1 , wherein the cancer is breast cancer. 
     
     
         4 . The method according to  claim 1 , wherein the cancer is colorectal cancer. 
     
     
         5 . The method according to  claim 1 , wherein the cancer is kidney cancer. 
     
     
         6 . The method according to  claim 1 , wherein the cancer is sarcoma. 
     
     
         7 . The method according to  claim 1 , wherein the cancer is lung cancer. 
     
     
         8 . A method for treating a cancer in a subject indeed thereof, comprising:
 administering to the subject an effective amount of a pharmaceutical composition comprising a polypeptide that binds to a peptide produced by cDNA of GenBank ACC No. NM_005201.3 or NM 007720.2.   
     
     
         9 . The method according to  claim 8 , wherein the pharmaceutical composition is administered at a dose of 5 mg to 5000 mg. 
     
     
         10 . The method according to  claim 8 , wherein the pharmaceutical composition is administered at a dose of 10 mg to 500 mg. 
     
     
         11 . The method according to  claim 8 , wherein the pharmaceutical composition is administered intravenously.

Join the waitlist — get patent alerts

Track US2020232973A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.